Skip to content

The Effectiveness of High-flow Nasal Cannula After Extubation in Patients

The Effectiveness of High-flow Nasal Cannula After Extubation in Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06746363
Enrollment
110
Registered
2024-12-24
Start date
2022-06-15
Completion date
2024-03-20
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Extubation Respiratory Failure

Keywords

post extubation, HFNC

Brief summary

Observe the current status of prolonged mechanical ventilation (PMV) patients using high-flow nasal cannula oxygen therapy (experimental group) or traditional oxygen therapy (control group) after extubation, and compare the differences in ventilator weaning rates between the two groups. Record the ROX index (SpO2/FiO2/RR) at 2, 6, 12, and 24 hours after extubation in PMV patients and explore whether statistical methods can predict the weaning outcome within seven days. Use statistical methods to analyze whether comorbidities in the PMV population affect ventilator weaning rates.

Interventions

None listed

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Patients over 20 years old and expected to undergo extubation.

Exclusion criteria

* Patients with tracheostomy who will use non-invasive or invasive ventilators immediately after extubation.

Design outcomes

Primary

MeasureTime frameDescription
ROX indexFrom enrollment to preliminary data compilation, lasting a total of 4 months.The oxygen concentration used before and after oxygen therapy adjustment is recorded as percent, accompanied by clinical and physiological parameter the patient's oxygen saturation (SpO₂) and respiratory rate (breaths per minute). Additionally, multiple measurements of the ROX index are performed, combining saturation (SpO₂), FiO₂, and respiratory rate to calculate and report the ROX index (SpO₂ / FiO₂ / RR).
P/F ratioFrom enrollment to preliminary data compilation, lasting a total of 4 months.Collect the arterial oxygen partial pressure (PaO₂, mmHg) from each patient's clinical arterial blood dialysis, and compare it with the oxygen concentration (%) being used at the time. The two values are then combined to calculate the P/F ratio (PaO₂, mmHg / FiO₂, decimal).

Other

MeasureTime frameDescription
Area Under Curve (AUC)From enrollment to the end of treatment at 1.5 yearhe Area Under the Curve (AUC) quantifies the overall performance of a model. The AUC ranges from 0 to 1, where an AUC of 0.5 indicates no discriminative power (random guessing), and an AUC of 1.0 indicates perfect discrimination that distinguishes between positive and negative classes without error. A higher AUC value suggests better model performance in distinguishing between classes, making it a widely used measure for assessing predictive accuracy in clinical and research datasets.
Receiver Operating Characteristic (ROC) curveFrom enrollment to the end of treatment at 1.5 yearthe Receiver Operating Characteristic (ROC) curve, the performance of two predictive models, Logistic Regression and Random Forest, in predicting HFNC (High-Flow Nasal Cannula) weaning success. The curve plots the True Positive Rate (Sensitivity) on the y-axis against the False Positive Rate (1 - Specificity) on the x-axis across various classification thresholds.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026